Business
Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021
Webcast to be held on Thursday, December 16 at 11:00 a.m. EST NEW YORK and SAN DIEGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc.
About this update from Zentalis Pharmaceuticals, Inc.
[{"type":"text","content":"Webcast to be held on Thursday, December 16 at 11:00 a.m. EST\nNEW YORK and SAN DIEGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, is hosting a virtual R&D Day on December 16, 2021 from 11:00 a.m. to 12:00 p.m. EST. Additional details on the event are summarized below. Zentalis’ management team along with three Key Opinion Leaders (KOLs) will present preclinical science from multiple programs and clinical updates on ZN-d5, the Company’s oral, selective BCL-2 inhibitor for hematologic malignancies, and ZN-e4, the Company’s oral EGFR inhibitor for non-small cell lung carcinoma. KOL Presenters: Tony Letai, M.D., Ph.D., Professor of Medicine, Hematologic Neoplasia/Malignancies, Dana-Farber Cancer Institute; Professor, Medicine, Harvard Medical SchoolRoss Levine, M.D., Chair, Memorial Sloan Kettering Cancer CenterKwok Wong, M.D., Ph.D., Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine at NYU Grossman School of Medicine; Director, Division of Hematology and Medical Oncology To register for the event, please visit the Investors page of Zentalis’ website, www.zentalis.com. A live webcast will also be accessible from the Investors page on the day of the event. Afterward, an archived webcast and presentation will be available for replay. About Zentalis Pharmaceuticals Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a WEE1 inhibitor for advanced solid tumors, ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC). Zentalis has licensed ZN-c3, ZN-c5 and ZN-d5 to its joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego. For more information, please visit www.zentalis.com. Follo...